大參林(603233.SH)：擬與關聯方共同增資天宸健康 孵化探索互聯網醫療相關業務
格隆匯6月15日丨大參林(603233.SH)公佈，廣州天宸健康科技有限公司(簡稱“天宸健康”)系公司的控股子公司，註冊資本為1000萬元，公司通過全資子公司廣東大參林醫藥貿易有限公司(簡稱“廣東大參林貿易”)間接持有其51.00%的股權；廣東康益百醫藥有限公司(簡稱“廣東康益百”)、大參林醫療健康(海南)有限公司(簡稱“大參林醫療健康”)均為公司全資子公司。
交易事項之一：公司擬將全資子公司廣東康益百、大參林醫療健康100%股權轉讓給公司控股子公司天宸健康，轉讓價格分別為590萬元、540萬元。該次股權轉讓完成後，廣東康益百、大參林醫療健康由公司全資子公司變為間接控股子公司，公司合併報表範圍未發生變更。
交易事項之二：在天宸健康完成對廣東康益百、大參林醫療健康100%股權的收購之後，天宸健康現有股東廣東大參林貿易、廣州雲眼智尚投資合夥企業(有限合夥)擬按照目前的持股比例、對天宸健康進行增資，增資總額為2億元，其中2億元計入註冊資本，0萬元計入資本公積。該次增資完成後，廣東大參林貿易持有天宸健康股份仍保持51%。
公司一直專注於中西成藥、蔘茸滋補藥材及中藥飲片、保健品、醫療器械及其他商品的連鎖零售業務，是全國規模領先的大型醫藥零售企業。為進一步拓展業務板塊，公司擬探索、孵化健康諮詢、線上問診、電子處方流轉平台等業務。
目前，互聯網醫療相關業務並不成熟，處於前期孵化階段，預計投入較大、投資週期較長、盈利前景尚不明確。如果上市公司單獨投資、孵化，可能產生持續虧損，加大經營風險。同時，該等業務與公司現有主營業務在經營模式、服務內容、管理制度、人才激勵等方面均存在一定程度差異，需要更多資源的投入。
因此，為了降低經營風險、保護上市公司和股東的利益，公司擬以控股子公司天宸健康為平台，孵化、探索互聯網醫療相關業務，並採取與關聯方共同增資的方式支持天宸健康發展，解決其初步的資金需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
